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ABSTRACT
Introduction. Antos et al. [7] have reported a case of suspected uniparental disomy leading to an initial erroneous diagnosis of 
Wilson’s Disease on the basis of genetic testing.  They discuss the usefulness of the 64Cu radioactive copper incorporation test 
as an often-overlooked diagnostic aid. 
Clinical reflections. Wilson’s Disease is difficult to diagnose because of its rarity, diverse clinical presentations, and the absence of 
a single fail-safe diagnostic test. The identification of mutations in the ATP7B gene has been an invaluable aid in the diagnosis, but 
genetic testing alone is not infallible, and should not be used as the sole diagnostic test in arriving at a diagnosis of Wilson’s Disease.
Clinical implications. The diagnosis of Wilson’s Disease must be based on a combination of findings that includes clinical 
history, clinical examination, and diagnostic testing. Genetic testing alone is insufficient. 
(Neurol Neurochir Pol 2020; 54 (5): 364–365)
For many neurologists (myself included), the fear of mis­
sing a diagnosis of Wilson’s Disease (WD) has always skulked, 
like a sinister spectre, in the shadowy subconscious of our 
neurologist brains.  
This fear is based partly on the rarity of WD, with its of­
ten reported prevalence of approximately 1:30,000 (although 
higher in some regions) [1, 2], which has fostered a propensity 
for WD to be diagnostically ‘out of sight, out of mind.’  Fur­
thermore, its ability to masquerade as diverse disorders due 
to its manifold clinical manifestations ranging from hepatic to 
neurological to psychiatric to a plethora of other presentations 
[3] has seemed often to render the diagnosis of WD an enigma 
worthy of Elgar.
To make matters worse, there has been no easy or certain 
diagnostic test for WD.  Screening with a serum ceruloplasmin 
level was simple, but neither sensitive nor specific enough to be 
relied upon as a sole diagnostic test [4]. A 24­hour urine copper 
determination was a better, though still imperfect, option, but 
was annoying and cumbersome for patients to collect, and was 
therefore often incompletely performed. 
Other tests, such as liver function tests and MRI, also 
were not sufficiently specific. The presence or absence of the 
characteristic Kayser­Fleischer rings also was not a fail­safe 
indication of WD, since individuals with only hepatic mani­
festations may not have yet developed this ophthalmological 
WD hallmark [5, 6]. Besides, Kayser­Fleischer rings are in fact 
not absolutely pathognomonic for WD [3]. Liver biopsy could 
be diagnostic, but entailed some risk, since coagulopathy often 
accompanied impaired liver function. Finally, and perhaps 
most dauntingly, the presence of effective treatment that could 
adequately control the disorder meant that missing, or even 
just delaying, the diagnosis could have tragic consequences.
But then the discovery that a mutation within the ATP7B 
gene is responsible for WD, and the ability to perform genetic 
testing for this mutation, arrived on the scene. Although ini­
tially very expensive and not readily available, with time both 
of these barriers were significantly overcome.  The subsequent 
documentation of many mutations – now numbering more 
than 700 [2] – complicated the testing and interpretation of the 
results, but still it appeared that the holy grail for the diagnosis 
of WD had been discovered.
The report by Antos et al. [7], however, serves as an im­
portant wake­up call and reminds us that there are some holes 
in our holy grail. It is accepted that genetic testing may not 
yet have identified all mutations responsible for WD. But the 
reverse, that genetic testing may actually falsely identify WD, 
has not been widely recognised. Antos et al. now provide us 
with an example. The possibility of uniparental isodisomy [8], 
the presence of two pathogenic mutations occurring on one 
allele, rather than arising from the usual two alleles, leading 
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to a mistaken diagnosis of WD (rather than a diagnosis of 
being a carrier), and subsequent inappropriate treatment, is 
not something that would come to the mind of most clinicians. 
But it did to Antos et al., and they have alerted the rest 
of us to this possibility. This is especially important given 
that some of the treatments employed in WD, such as peni­
cillamine and trientine, possess the potential for serious and 
even life­threatening adverse effects [2, 3].
So, how does one avoid this potentially devastating error? 
Antos et al. go on to provide us with a possible answer in the 
form of the 64Cu radioactive copper incorporation test. This is 
not a new test [9] but has been used rarely by most clinicians, 
partly because of difficulty with access to the isotope, and 
partly due to the complex nature of the test, which extends 
over multiple days.  
The lesson to be learned here is not that the radioactive 
copper incorporation test needs to be performed on every indi­
vidual suspected of having WD; that would be both impractical 
and unnecessary. However, in individuals in whom genetic 
testing suggests a diagnosis of WD but where the clinical and 
laboratory picture is not entirely consistent or raises some 
questions, this is a test that should not be forgotten. 
It should be noted that the case presented by Antos et al. 
has some strings unfortunately left untied. The clinical picture 
was especially complicated and confusing, with additional co­
morbid diagnoses of idiopathic immunodeficiency syndrome, 
coeliac disease, and ulcerative colitis. Genetic testing of both 
parents to confirm the presence of two mutations (presumably 
on one allele) in one of the parents could have been confirma­
tory, but was impossible since the father was unknown and the 
mother apparently unavailable for testing. Liver biopsy during 
life was not performed because of concerns regarding coagu­
lopathy, and autopsy was not performed following death, so 
a more secure diagnosis for the liver disease was not possible. 
As noted by the authors, this case underlines that genetic 
testing alone should not be used as the sole criterion for the 
diagnosis of WD, and that an appropriate combination of 
clinical history, clinical examination, and laboratory findings, 
including genetic testing if needed, remains necessary for the 
accurate diagnosis of WD. This very important point is one 
that has also been made and emphasised by others [10, 11].  
However, Antos et al. have brought to our attention a par­
ticularly important note of caution: although genetic testing 
may significantly reduce the risk of overlooking a diagnosis of 
WD, it also can impose a risk of incorrectly diagnosing WD. 
In summary, this case presentation is a helpful and in­
structive lesson that will strengthen the horsehair that secures 
the sword of Damocles dangling above us with regard to the 
diagnosis – or misdiagnosis – of WD. 
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